Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available

Next Previous
Trial Profile

Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMC CS4 (Primary)
  • Indications Advanced breast cancer; Carcinoma; Colorectal cancer; Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Sarcoma; Solid tumours
  • Focus First in man; Pharmacokinetics
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 23 Feb 2021 Results published in the Investigational New Drugs
  • 20 Jul 2018 Status changed from active, no longer recruiting to completed.
  • 15 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top